Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) AI Stock Analysis

• Market Cap: HK$11.23B
• Dividend Yield: N/A
• Average Volume (3M): 488.12K
• Price to Earnings (P/E): 75.0
• Beta (1Y): 1.08
• Revenue Growth: 48.38%
• EPS Growth: N/A
• Country: HK
• Employees: 1,117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.13
• Shares Outstanding: 110,781,920
• 10 Day Avg. Volume: 755,126
• 30 Day Avg. Volume: 488,121
• PEG Ratio: -0.87
• Price to Book (P/B): 3.81
• Price to Sales (P/S): 3.24
• P/FCF Ratio: 18.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$32.00 ▲(18.34% Upside)

Biocytogen Pharmaceuticals shows a strong financial performance with significant profitability and revenue growth, which is the most significant factor in the overall score. Technical analysis indicates mixed momentum, while the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Sustained revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and stability.

Profitability

Improved profitability suggests efficient cost management and operational success, enhancing the company's ability to reinvest in growth opportunities.

Cash Flow Management

Robust cash flow growth supports financial flexibility, enabling strategic investments and reducing reliance on external financing.

Negative Factors

Leverage Concerns

Elevated leverage may limit financial flexibility and increase risk, necessitating careful management to maintain long-term financial health.

Profitability Volatility

Volatile profitability can impact predictability of earnings, affecting investor confidence and the company's ability to plan long-term.

Leverage Monitoring

Ongoing leverage monitoring is crucial to prevent financial strain, ensuring the company can sustain growth and withstand economic fluctuations.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.

How the Company Makes Money

Biocytogen Pharmaceuticals generates revenue primarily through the development and commercialization of its therapeutic products, which include monoclonal antibodies. The company earns money by partnering with other pharmaceutical firms for drug development, licensing its technologies, and receiving milestone payments as products progress through clinical trials. Additionally, Biocytogen may generate revenue through the sale of its proprietary drug candidates, once they receive regulatory approval. Strategic collaborations with larger pharmaceutical companies also provide financial support, including upfront payments and royalties on future sales, contributing significantly to its earnings.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview

Summary

Biocytogen Pharmaceuticals demonstrates a positive financial trajectory with improvements across income statement, balance sheet, and cash flow metrics. The company has achieved significant profitability and revenue growth, supported by efficient operations and cash management. However, maintaining leverage and ensuring consistent cash flow generation will be crucial for sustaining long-term financial health.

Income Statement

Biocytogen Pharmaceuticals has shown a strong improvement in its income statement metrics over the TTM period. The gross profit margin is robust at 79.5%, indicating effective cost management. The net profit margin has improved significantly to 11.1%, reflecting enhanced profitability. Revenue growth rate is healthy at 9.7%, suggesting positive business momentum. EBIT and EBITDA margins have also improved, indicating operational efficiency. However, historical volatility in profitability remains a concern.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.69, which is manageable but slightly elevated compared to previous years. Return on equity has improved to 15.3%, indicating better utilization of shareholder funds. The equity ratio stands at 35.9%, reflecting a stable capital structure. While improvements are evident, the company should continue to monitor its leverage to maintain financial stability.

Cash Flow

Cash flow metrics have shown positive trends, with a strong free cash flow growth rate of 32.1% in the TTM period. The operating cash flow to net income ratio is 0.82, indicating good cash conversion. The free cash flow to net income ratio is 0.88, reflecting efficient cash management. Despite these improvements, the company should focus on sustaining cash flow generation to support future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.19B	980.45M	716.91M	533.88M	354.56M	253.54M
Gross Profit	946.48M	761.52M	506.03M	391.75M	247.44M	166.99M
EBITDA	382.48M	303.80M	-97.87M	-465.86M	-378.12M	-328.64M
Net Income	132.21M	33.54M	-382.95M	-602.16M	-545.58M	-542.97M
Balance Sheet
Total Assets	2.49B	2.42B	2.45B	2.80B	2.30B	2.33B
Cash, Cash Equivalents and Short-Term Investments	486.84M	381.18M	408.09M	611.27M	566.45M	957.41M
Total Debt	614.18M	570.28M	544.11M	415.28M	89.80M	463.80M
Total Liabilities	1.59B	1.58B	1.66B	1.65B	1.05B	868.28M
Stockholders Equity	892.04M	834.06M	785.89M	1.15B	1.25B	1.45B
Cash Flow
Free Cash Flow	338.66M	174.12M	-203.26M	-543.94M	-564.45M	-531.73M
Operating Cash Flow	385.07M	211.25M	-76.65M	-303.27M	-365.78M	-225.31M
Investing Cash Flow	-188.05M	-137.12M	-100.28M	-153.74M	-84.13M	-188.18M
Financing Cash Flow	-165.85M	-92.03M	-37.82M	587.20M	219.44M	868.44M

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.04
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Neutral. The current price of 27.04 is below the 20-day moving average (MA) of 31.31, below the 50-day MA of 28.52, and above the 200-day MA of 21.32, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 41.23 is Neutral, neither overbought nor oversold. The STOCH value of 15.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2315.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	66 Neutral	HK$11.23B	75.05	16.13%	―	48.38%	―
1672	54 Neutral	HK$14.50B	-45.44	-12.74%	―	-76.58%	-4.90%
2171	53 Neutral	HK$9.02B	-15.42	-42.46%	―	1219.19%	25.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2162	41 Neutral	HK$15.32B	-52.74	-8.79%	―	964.40%	65.90%
2157	40 Underperform	HK$9.93B	-48.49	-21.42%	―	240.05%	-140.09%

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events

Biocytogen’s Partner IDEAYA Receives FDA Clearance for IDE034 Clinical Trial

Biocytogen Pharmaceuticals announced that its partner, IDEAYA Biosciences, has received FDA clearance for an IND application to initiate a Phase 1 clinical trial of IDE034, a bispecific B7H3/PTK7 antibody-drug conjugate. This milestone underscores Biocytogen’s technical capabilities and highlights the potential of IDE034 in treating various solid tumors, marking a significant advancement in precision-targeted therapeutic strategies.

Biocytogen Pharmaceuticals Sets A Share Offering Price and Size

Biocytogen Pharmaceuticals has announced the determination of the offer size and price for its A Share Offering, with plans to issue 47,500,000 new A Shares at RMB26.68 per share. This strategic move, following preliminary price consultations, aims to enhance the company’s market presence and leverage its fundamentals, market conditions, and industry valuations, potentially impacting its operations and positioning within the biotechnology sector.

Biocytogen Pharmaceuticals Submits A Share Prospectus Amid Financial Growth

Biocytogen Pharmaceuticals has submitted a prospectus for the initial public offering of A shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The financial information reveals a significant improvement in the company’s financial performance, with a notable increase in operating income and a shift from a loss to a profit, indicating strong growth and potential positive implications for stakeholders.

Biocytogen Pharmaceuticals Announces A Share Issuance on Shanghai Stock Exchange

Biocytogen Pharmaceuticals has announced the preliminary price consultation period for its proposed issuance of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company plans to issue 47,500,000 new A Shares, representing a significant portion of its total share capital. This move is expected to enhance the company’s financial position and market presence, potentially impacting stakeholders by increasing investment opportunities and expanding its shareholder base.

Biocytogen Pharmaceuticals Approves Key Resolutions at 2025 EGM

Biocytogen Pharmaceuticals held its first extraordinary general meeting of 2025, where several key resolutions were approved by shareholders. The meeting, conducted both physically and virtually, saw the approval of the proposed issuance of A Shares and amendments to the company’s Articles of Association, reflecting strategic moves to enhance its market presence and operational framework.

Biocytogen Pharmaceuticals to Issue A Shares on Sci-Tech Board

Biocytogen Pharmaceuticals has announced plans to issue A Shares and list them on the Sci-Tech Board, with the approval process completed by the Shanghai Stock Exchange and CSRC. The proceeds from this issuance will be used to fund various projects, including drug development and evaluation, and to supplement working capital. Additionally, the company plans to amend its Articles and abolish its Supervisory Committee in alignment with the new share issuance.

Biocytogen Pharmaceuticals Announces 2025 Extraordinary General Meeting

Biocytogen Pharmaceuticals has announced its 2025 first extraordinary general meeting, scheduled for November 19, 2025. The meeting will address several key resolutions, including the proposed issuance of A Shares and amendments to company articles and procedural rules. These changes indicate a strategic move towards listing on the Sci-Tech Board, which could enhance the company’s market presence and operational efficiency. Additionally, the meeting will consider the abolishment of the Supervisory Committee, suggesting a shift in governance structure that may impact stakeholder engagement and company oversight.

Biocytogen Pharmaceuticals Gains CSRC Approval for A Share Issue

Biocytogen Pharmaceuticals has received approval from the China Securities Regulatory Commission (CSRC) for the registration of its proposed initial public issue of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. This development is a significant step for the company, although the completion of the share issue is contingent on certain conditions. Stakeholders are advised to exercise caution, and further updates will be provided as necessary.

Biocytogen Pharmaceuticals Gains Approval for A Shares Issuance on Shanghai Sci-Tech Board

Biocytogen Pharmaceuticals has received approval from the Sci-Tech Board of the Shanghai Stock Exchange for its proposed issuance of A Shares. This development marks a significant step in the company’s strategic financial initiatives, potentially enhancing its market presence and offering new opportunities for stakeholders, although the completion of the share issue is subject to certain conditions.

Biocytogen Pharmaceuticals Advances A Share Offering Plans

Biocytogen Pharmaceuticals has announced the progress of its proposed initial public offering of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company has submitted the necessary prospectus, but the completion of the share issue is subject to certain conditions. Stakeholders are advised to exercise caution as the offering may or may not be completed.